Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13175197 | 0.79 | KDM4E (0.45) | MAPK8KDM4ELMNAHSP90AA1HSP90AB1 | |
| SCHEMBL7895323 | 0.79 | MAPK8 (0.59) | MAPK8KDM4ELMNAHSP90AA1HSP90AB1 | |
| SCHEMBL11711087 | 0.78 | PTK2 (0.49) | MAPK8KDM4ELMNAHSP90AA1HSP90AB1 | |
| SCHEMBL14453104 | 0.77 | MAPK8 (0.40) | MAPK8KDM4ELMNAHSP90AA1HSP90AB1 | |
| SCHEMBL4069156 | 0.75 | KDM4E (0.41) | MAPK8KDM4ELMNAHSP90AA1HSP90AB1 | |
| SCHEMBL29951716 | 0.75 | ALDH1A1 (0.44) | MAPK8KDM4ELMNAHSP90AA1HSP90AB1 | |
| SCHEMBL11486599 | 0.73 | KDM4E (0.51) | MAPK8KDM4ELMNAHSP90AA1HSP90AB1 | |
| SCHEMBL14642747 | 0.72 | KDM4E (0.44) | MAPK8KDM4ELMNAHSP90AA1HSP90AB1 | |
| SCHEMBL12513100 | 0.72 | MAPK8 (0.47) | MAPK8KDM4ELMNAHSP90AA1HSP90AB1 | |
| SCHEMBL9651921 | 0.71 | PGK1 (0.43) | KDM4EPTK2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| EP-2216407-B1 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8344125-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120214861-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120107272-A1 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20110201798-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110166198-A1 | RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110092565-A1 | METHOD OF TREATING NEURODEGENERATIVE DISEASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110054160-A1 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100179309-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-07-15 | — | — | US | disclosed |
| US-7723509-B2 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to target tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7595306-B2 | Method of treating neurodegenerative disease | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-29 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | NSUN2, RNGTT, DCLRE1B | MAPK8 3195/4885KDM4E 3507/4885LMNA 3431/4885 |
| US-20110054160-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | MAPK8 3462/4885KDM4E 3864/4885LMNA 747/4885 |
| US-20110201798-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | MAPK8 3462/4885KDM4E 3864/4885LMNA 747/4885 |
| US-20120214861-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | MAPK8 4179/4885KDM4E 4076/4885LMNA 34/4885 |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | MAPK8 4213/4885KDM4E 4097/4885LMNA 56/4885 |
| US-20130053334-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | DNMT1, FANCI, PCNA | MAPK8 3833/4885KDM4E 2182/4885LMNA 3840/4885 |
| US-20110166198-A1 | RNA COMPOSITIONS FOR MODULATING IMMUNE RESPONSE | EIF2AK2, IRF3, NSUN2 | MAPK8 2689/4885KDM4E 2930/4885LMNA 1756/4885 |
| US-20070161595-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | MAPK8 4065/4885KDM4E 3524/4885LMNA 1653/4885 |
| US-20100179309-A1 | MODIFIED iRNA AGENTS | HNRNPA0, HNRNPA1, SNRPA | MAPK8 3564/4885KDM4E 4093/4885LMNA 83/4885 |
| US-20120107272-A1 | SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES | IFNAR1, DDX18, STING1 | MAPK8 1376/4885KDM4E 3656/4885LMNA 4707/4885 |
| US-20100267810-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | SMN1; SMN2, CLN6, INA | MAPK8 4179/4885KDM4E 4076/4885LMNA 34/4885 |
| US-20110092565-A1 | METHOD OF TREATING NEURODEGENERATIVE DISEASE | SNCA, PARK7, NLN | MAPK8 4065/4885KDM4E 3524/4885LMNA 1653/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | MAPK8 3493/4885KDM4E 3196/4885LMNA 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.